Featured

As debate rages, PBM sees big savings in biosimilars

As debate rages over drug prices, one of the country’s largest pharmacy benefit managers is touting biosimilars as a way of achieving significant savings over the next five years. » Read More

Express Scripts: Lack of competition led to price gouging on EpiPens

The experience of Mylan, the pharmaceutical company under fire for hiking the price of a life-saving allergy medicine, reinforces the importance of competition in the marketplace, one of the country’s largest pharmacy benefit managers said. » Read More

Survey: Most employers believe federal oversight would boost drug costs

Recent survey results conducted by North Star Opinion Research and released by an industry association confirm that 60 percent of U.S. employers believe new federal oversight would lead to higher prescription-drug costs. » Read More

Single industry-sponsored meal associated with increased brand-name prescriptions

A single industry-sponsored meal is enough to sway a doctor to prescribe a brand-name drug rather than a cheaper but just as effective generic, a study by the University of San Francisco has found. » Read More

Public opinion of drug makers lowest in 16 years, recent Gallup poll suggests

If drug manufacturers ever wonder whether they have a collective image problem, the answer is yes, according to a recent Gallup poll. » Read More

Drug price ballot initiative 'vague and poorly conceived' say activists

A ballot initiative supporters claim will lower drug prices in California is vague and poorly conceived, said a group with a long history of advocating for better cures and treatment for HIV and hepatitis C. » Read More

Drug restrictions cut costs without negative impact on patients: study

A majority of health care plans and programs with a drug exclusion policy have been successful, reducing costs and not negatively impacting patient care, concludes a new study published in The American Journal of Managed Care. » Read More

Managing high cost of speciality drugs key challenge for employers, payers

Managing and monitoring the increasingly high cost of speciality drugs will be a key challenge to control insurance prices over the next two years, say employers and third party payers. » Read More

Medicare Part D premiums to see only slight rise in 2017

WASHINGTON, D.C. -- Medicare Part D premiums will see only a modest rise in 2017, despite costs to taxpayers growing faster than parts A and B, the Centers for Medicare and Medicaid Services (CMS) recently said in a statement. » Read More

Medicare premium to stay stable

With only the slightest of increases, Medicare recently announced that the average monthly cost for a Medicare Part D prescription drug plan in 2017 is projected to remain reasonably stable at approximately $34. » Read More

+ More News

Latest News

Allergan announces acquisition of Akarna Therapeutics

Allergan Inc. recently announced the acquisition of Akarna Therapeutics for an upfront payment of $50 million.   » Read More

FDA approves Abbott’s Freestyle Libre Pro system

Abbott announced this week that its FreeStyle Libre Pro system, a groundbreaking continuous glucose monitoring (CGM) system designed for patients with diabetes, has been approved by the U.S. Food and Drug Administration (FDA).re » Read More

Perrigo agrees to exclusive licensing agreement for Highland’s Tarex technology

Perrigo Co. this week announced that it has agreed to an exclusive licensing agreement with Highland Pharmaceuticals LLC for its methamphetamine (meth) blocking technology called Tarex. » Read More

Jazz JZP-110 trial finalizes enrollment

Jazz Pharmaceuticals plc recently reported that enrollment for its two Phase 3 clinical trials for JZP-110 has been finalized. » Read More

Amgen announces top-line CLARION trial results

Amgen recently reported top-line results of its Phase 3 CLARION trial that was designed to assess KYPROLIS (carfilzomib), melphalan and prednisone (KMP), Amgen's new investigational regimen, while comparing it to Velcade (bortezomib). » Read More

Tarix Orphan receives Orphan Drug Status for TXA127 from FDA

Tarix Orphan LLC recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status to TXA127, the company’s prospective treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. » Read More

Armetheon releases results of Phase 1 tecarfarin trial

Armetheon Inc., a specialty pharmaceutical company that focuses on the development of novel small molecule drugs for the treatment of cardiovascular diseases, recently released the results of its Phase 1 clinical trial assessing how the pharmacokinetics (PK) of tecarfarin and of warfarin is affected by severe chronic kidney disease (CKD). » Read More

NAMZARIC now available in prescription in U.S.

Allergen plc recently announced that NAMZARIC is now available through prescription in pharmacies across the United States. » Read More

EMA accepts Mylan, Biocon MAA for Trastuzumab for review

Mylan N.V. and Biocon Ltd. recently announced that Mylan’s Marketing Authorization Application (MAA) for Trastuzumab has been accepted by the European Medicines Agency (EMA) for review.  » Read More

PharmaMar submits MAA for Aplidin to EMA

PharmaMar recently submitted a Marketing Authorization Application (MAA) for Aplidin to the European Medicines Agency (EMA). » Read More

+ More News